Litigation Details for Otsuka Pharmaceutical Co., Ltd. v. Ajanta Pharma Ltd. (D. Del. 2019)

Otsuka Pharmaceutical Co., Ltd. v. Ajanta Pharma Ltd. (D. Del. 2019)

Docket		Date Filed	2019-10-11
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	10,307,419; 7,888,362; 8,349,840; 8,618,109; 9,839,637
Link to Docket	External link to docket

Details for Otsuka Pharmaceutical Co., Ltd. v. Ajanta Pharma Ltd. (D. Del. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-10-11	1	Complaint	the ’840 patent”), 8,618,109 (“the ’109 patent”), 9,839,637 (“the ’637 patent”), and 10,307,419 (“the ’…civil action for patent infringement of U.S. Patent Nos. 7,888,362 (“the ’362 patent”), 8,349,840 (“the… ’419 patent”) (collectively, “patents in suit”), arising under the United States patent laws, Title … The Patents In Suit 16. The United States Patent and Trademark Office …of the ’362 patent is attached as Exhibit A. 17. Otsuka owns the ’362 patent through assignment	External link to document
2019-10-11	4	Patent/Trademark Report to Commissioner of Patents	,349,840; 8,618,109; 9,839,637; 10,307,419. (nmg) (Entered: 10/15/2019) 11 October 2019 PACER … Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,888,362; 8,349,840… 11 October 2019 1:19-cv-01939 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Otsuka Pharmaceutical v. Ajanta Pharma, 1:19-cv-01939: Litigation Summary and Patent Analysis

Last updated: September 26, 2026

Otsuka Pharmaceutical Co., Ltd. sued Ajanta Pharma Ltd. in the U.S. District Court for the District of Delaware in October 2019 under the Hatch-Waxman Act. The case arose from Ajanta’s abbreviated new drug application, or ANDA, for a generic version of Otsuka’s Rexulti, whose active ingredient is brexpiprazole. The action was part of a broader group of Otsuka patent suits against generic-drug applicants.

The publicly available docket does not show a reported trial verdict or a judicial determination that Ajanta infringed a valid Otsuka patent. The case proceeded as an ANDA patent dispute and was ultimately resolved without a publicly reported merits opinion. The public record does not disclose the commercial terms of any resolution or establish an authorized generic-entry date.

What drug was targeted in Otsuka v. Ajanta?

The litigation concerned brexpiprazole tablets, marketed by Otsuka as Rexulti.

Item	Detail
Brand	Rexulti
Active ingredient	Brexpiprazole
Dosage form	Oral tablets
NDA holder	Otsuka Pharmaceutical Co., Ltd.
Generic applicant	Ajanta Pharma Ltd.
Statutory basis	Hatch-Waxman ANDA litigation
Court	U.S. District Court for the District of Delaware
Civil action	1:19-cv-01939
Filing period	2019
Primary commercial issue	Whether Ajanta could obtain FDA approval and launch a generic brexpiprazole product

Rexulti is approved for schizophrenia and as an adjunctive treatment for major depressive disorder. The product is regulated under an NDA, while Ajanta’s proposed product was reviewed through the ANDA pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act.[1]

What patents protected Rexulti in the Ajanta litigation?

The litigation involved Otsuka’s Orange Book-listed patent rights covering brexpiprazole and related pharmaceutical products. The operative patent claims depended on the specific ANDA certifications and the patent allegations pleaded against Ajanta.

In Hatch-Waxman litigation, a generic applicant typically sends a Paragraph IV notice when it asserts that a listed patent is invalid, unenforceable, or would not be infringed by the proposed product. The NDA holder can then file suit within 45 days to trigger the statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii).[2]

The public litigation record should be read together with the FDA Orange Book because the Orange Book identifies patents listed by the NDA holder, while the complaint and docket establish which patents were asserted against Ajanta. Orange Book listings alone do not prove that every listed patent was asserted in the case.

What types of patent claims were commercially relevant?

The Rexulti patent estate potentially implicated several categories of protection:

1. Composition-of-matter claims covering brexpiprazole or related chemical subject matter.
2. Pharmaceutical-composition claims covering tablets and excipient systems.
3. Method-of-use claims covering treatment of schizophrenia or adjunctive treatment of major depressive disorder.
4. Patent-term and regulatory-exclusivity rights affecting the timing of FDA approval.

For an ANDA applicant, the practical risk depends on the claims actually asserted. A composition patent can block the generic product broadly. A formulation patent may apply only to a particular tablet composition or manufacturing process. A method-of-use patent may create a narrower risk if the ANDA includes the patented indication or if the proposed labeling does not adequately carve it out.

When did Otsuka file against Ajanta?

Otsuka filed the action in 2019 after receiving Ajanta’s Paragraph IV certification notice. The case number, 1:19-cv-01939, identifies the Delaware action but does not itself identify the asserted patents or the precise date of the notice.

The filing placed Ajanta’s ANDA under the statutory litigation stay. The stay generally prevents FDA approval for up to 30 months unless the court resolves the case earlier, the patents expire, or another statutory event terminates the stay.[2]

What was the likely effect of the 30-month stay?

The 30-month stay delayed FDA approval of Ajanta’s ANDA while the parties litigated or negotiated. The stay did not automatically prevent Ajanta from preparing for launch, and it did not itself establish that Otsuka’s patents were valid or infringed.

The stay also created settlement leverage. Otsuka could preserve the branded product’s market position during the statutory period, while Ajanta could seek a license, a negotiated entry date, or a resolution that avoided the cost and risk of trial.

Was there a Paragraph IV challenge?

Yes. The case was an ANDA patent action, which indicates that Ajanta sought FDA approval through a patent certification framework. The litigation was therefore based on a Paragraph IV certification or a substantially equivalent patent challenge under the Hatch-Waxman process.

A Paragraph IV certification is not a final ruling that a patent is invalid. It is an assertion by the ANDA applicant that the relevant listed patent should not prevent approval of the proposed generic product. The patent holder must then prove infringement and defend validity if the case proceeds to judgment.

Did the court find infringement or patent invalidity?

No publicly reported merits decision establishes that Ajanta infringed an enforceable Otsuka patent in this action. The docket does not provide a reported trial judgment comparable to a Federal Circuit or district-court opinion addressing the validity and infringement of the asserted Rexulti patents.

That distinction matters. A dismissal, settlement-based termination, or stipulated resolution does not establish:

• that Otsuka’s asserted claims were valid;
• that Ajanta’s proposed product infringed;
• that Ajanta’s ANDA was rejected by FDA;
• that Ajanta permanently abandoned its generic program; or
• that other generic applicants would face the same result.

What was the litigation outcome?

The action ended without a publicly reported adjudication on the merits. The public record does not disclose the full economic terms of the resolution.

The available record does not establish whether the parties agreed to:

• a licensed early-entry date;
• a launch date tied to patent expiration;
• a royalty-bearing license;
• an authorized-generic arrangement;
• a no-challenge provision;
• a supply agreement; or
• a confidential commercial settlement.

Confidential Hatch-Waxman settlements are common. A docket termination therefore has limited value in predicting the precise generic launch date unless the settlement agreement, FTC filing, or later FDA approval record discloses that date.

Did the settlement permit generic Rexulti entry?

The public case record does not establish an authorized entry date for Ajanta’s brexpiprazole product. A settlement may resolve the lawsuit without resulting in immediate market entry.

Commercial entry depends on several separate events:

1. FDA approval of the ANDA.
2. Expiration or resolution of patents that remain enforceable.
3. Compliance with any labeling restrictions.
4. Satisfaction of manufacturing and inspection requirements.
5. The terms of any license or settlement.
6. Ajanta’s commercial decision to launch.

A litigation dismissal should not be treated as evidence that the generic entered the market. FDA approval records and product-launch disclosures are required to confirm commercial availability.

What is the FDA and Orange Book status relevant to the case?

FDA approval of the reference product and Orange Book patent listings formed the regulatory foundation of the dispute. FDA’s Orange Book identifies approved drug products, reference products, therapeutic-equivalence information, and patents submitted by NDA holders.[3]

For Rexulti, the relevant regulatory questions are:

Regulatory issue	Business significance
ANDA approval	Determines whether Ajanta can legally market its generic
Paragraph IV certification	Creates potential patent litigation exposure
30-month stay	Delays FDA approval after timely patent litigation
Listed method-of-use patents	May require a section viii carve-out
Product-specific patents	Can delay approval beyond basic exclusivity
REMS or labeling requirements	Can affect approval and launch execution

A patent listing is not equivalent to a confirmed patent term. Expiration must be verified against the patent record, terminal disclaimers, patent-term adjustment, pediatric extension, and any court order or settlement affecting enforcement.

How strong was Otsuka’s patent estate?

Otsuka’s position was commercially meaningful because Rexulti is a branded CNS product with potentially broad chemical and use coverage. The strength of the estate, however, depended on claim scope and the specific defenses raised by Ajanta.

Strengths

• A valid composition patent can block substitution across multiple manufacturers.
• A chemically defined active ingredient can create significant design-around difficulty.
• Method-of-use claims may preserve protection for labeled indications after composition protection expires.
• Formulation claims can create secondary barriers where the generic product closely follows the reference formulation.
• Multiple patents can increase settlement leverage even if individual claims face validity risk.

Weaknesses

• Later-expiring formulation patents may cover only narrow claim limitations.
• Method-of-use patents can be weakened by a proper section viii carve-out.
• Paragraph IV challenges can attack obviousness, written description, enablement, anticipation, or claim construction.
• A generic applicant may avoid infringement by changing excipients, tablet characteristics, labeling, or manufacturing steps.
• Patent-term calculations can materially narrow the period of enforceable protection.

The record does not support assigning a probability of validity or infringement without the asserted patent claims, Ajanta’s notice letter, claim-construction positions, expert reports, and the final settlement terms.

Which companies were challenging Rexulti patents?

Otsuka’s 2019 Delaware filings reflected broader generic interest in brexpiprazole. The Ajanta case was one of several ANDA disputes involving generic applicants. The competitive threat included companies seeking approval for generic brexpiprazole tablets through the ANDA pathway.

The main market variables were:

• the number of approved ANDAs;
• whether any applicant received first-filer status;
• settlement-based launch dates;
• the availability of multiple generic suppliers;
• manufacturing capacity for brexpiprazole;
• the timing of Paragraph IV certifications; and
• payer substitution after launch.

Multiple generic approvals would create substantially greater price pressure than a single licensed entrant. A first entrant could capture disproportionate volume before additional approvals, particularly if it launched under an authorized-generic or early-entry arrangement.

What generic-entry risks did Otsuka face?

The case created four principal risks for Otsuka.

Revenue erosion

Brexpiprazole tablets are vulnerable to substitution once an AB-rated generic is approved and marketed. The magnitude of erosion would depend on the number of entrants, payer contracts, rebate structures, and whether Otsuka introduced an authorized generic.

Patent-estate erosion

A successful Paragraph IV challenge could invalidate or narrow claims with effects extending beyond Ajanta. Although a district-court judgment binds the parties directly, its reasoning can influence parallel cases and settlement negotiations.

Labeling workarounds

If only method-of-use patents remained, Ajanta could seek approval with a carved-out label. The commercial impact would depend on whether pharmacies and payers could still substitute the generic for prescriptions written for the protected use.

Manufacturing competition

Brexpiprazole is an orally administered small molecule, so generic competition is generally more feasible than for a complex biologic or long-acting injectable. Manufacturing, quality-control, bioequivalence, and supply-chain execution remain important, but the product does not present the same technical barriers as a biosimilar or depot formulation.

Did biosimilar risk apply?

No. Rexulti is a chemically synthesized small-molecule drug, not a biologic. The relevant pathway was an ANDA under section 505(j), not a biosimilar application under the Public Health Service Act.

The case therefore involved generic-substitution risk rather than biosimilar interchangeability, biologic exclusivity, or reference-product exclusivity under section 351.

What does the case mean for generic launch analysis?

The case should be treated as a closed Hatch-Waxman dispute with no publicly reported merits ruling and no publicly established Ajanta launch date. The litigation confirms that Ajanta challenged Otsuka’s patent position, but it does not independently establish the enforceable patent end date or commercial timing.

For investment and licensing analysis, the key conclusions are:

• Otsuka used patent litigation to delay or control generic brexpiprazole entry.
• Ajanta’s Paragraph IV position created a statutory 30-month approval barrier.
• The case did not produce a reported ruling invalidating the Rexulti patent estate.
• The public docket does not disclose a reliable Ajanta entry date.
• Generic entry analysis must incorporate all remaining Orange Book patents, FDA approval status, settlement terms, and other ANDA applicants.
• The product’s small-molecule tablet format creates meaningful long-term generic substitution risk once patent and regulatory barriers are cleared.

Key Takeaways

• Otsuka Pharmaceutical sued Ajanta Pharma in Delaware in 2019 over an ANDA for generic brexpiprazole, the active ingredient in Rexulti.
• The case was a Hatch-Waxman Paragraph IV dispute.
• The litigation triggered the statutory 30-month stay on FDA approval.
• No publicly reported merits decision establishes infringement, validity, or invalidity in Ajanta’s favor.
• The case ended without publicly disclosed commercial settlement terms.
• The public record does not establish Ajanta’s authorized generic-entry date.
• Rexulti is a small-molecule product, so biosimilar law does not apply.
• Orange Book listings, patent-term calculations, FDA approval records, and settlement disclosures must be reviewed together to assess generic-launch timing.

FAQs

Was Ajanta the first company to challenge Rexulti patents?

The case identifies Ajanta as a Paragraph IV ANDA challenger, but the public docket alone does not establish whether Ajanta was the first filer or had 180-day generic exclusivity.

Can Ajanta launch generic brexpiprazole after the lawsuit ended?

Case termination alone does not authorize launch. Ajanta would need FDA approval and any required license or patent-resolution rights.

Does the case establish that Rexulti patents were valid?

No. Without a merits judgment, the litigation does not establish validity, infringement, or enforceability.

Could a generic company launch with a carved-out label?

Potentially. A section viii labeling carve-out may be available for certain method-of-use patents, subject to FDA acceptance and the scope of the remaining claims.

Is Otsuka’s Rexulti exclusivity the same as patent protection?

No. FDA regulatory exclusivity and patent protection are separate rights. A product may lose regulatory exclusivity while remaining protected by enforceable patents, or retain patent protection after regulatory exclusivity expires.

References

1. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application (ANDA). https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda

2. 21 U.S.C. § 355(j). Abbreviated applications for new drugs.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. U.S. District Court for the District of Delaware. (2019). Otsuka Pharmaceutical Co., Ltd. v. Ajanta Pharma Ltd., No. 1:19-cv-01939.